Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers [Phase 1]

View source ↗

Summary

Phase 1 safety, pharmacokinetics, and pharmacodynamics study of HL-032 in healthy male volunteers completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• HL-032

Snippet

Sponsor: HanAll BioPharma Co., Ltd. | Conditions: Growth Hormone Deficiency | Phase 1 | Status: COMPLETED